Insulin Detemir, Recombinant

Modality

Insulin Detemir, Recombinant

Description of Insulin Detemir, Recombinant

Insulin detemir, as a chemically modified form of insulin, is a long-acting basal insulin. Insulin detemir differs from human insulin in which amino acid B29 is modified with a fatty acid (myristic acid), and position B30 threonine (Thr) is deleted. Insulin detemir was developed by Novo Nordisk, and approved in 2005 for glycemic control in diabetes mellitus patients, with the brand name Levemir.

Synonyms

Levemir, Levemir FlexPen, Levemir FlexTouch, Levemir InnoLet, Levemir Penfill, Detemir, Insulin detemir (genetical recombination), Insulin detemir (USAN/INN), LysB29-tetradecanoyl des-(B30) human insulin, NN 304, NN-304, NN729, 诺和平, レベミル

Amino Acid Sequence of Insulin Detemir

Based on the human insulin sequence, insulin detemir is deleted at position B30Thr and linked to a C14 fatty acid chain at position B29, which prolongs its duration of action.

Fig 1. Structure formula of insulin detemir

Expression System of Insulin Detemir

Typical Products	Active Substance	Expression System
Levemir	Insulin Detemir	Yeast (Saccharomyces cerevisiae)

Formulation of Insulin Detemir

Inactive ingredients (Excipients) in Levemir (Vial, Prefilled Cartridge)

Dibasic sodium phosphate, glycerin, metacresol, phenol, sodium chloride, zinc, and hydrochloric acid or sodium hydroxide (pH 7.4).

All Categories

Insulin Detemir, Recombinant

Modality